Researchers disclosed a first‑in‑class GAS41 (YEATS4) inhibitor for non‑small‑cell lung cancer and published selective Bruton tyrosine kinase (BTK) inhibitors that block invasion and progression in glioblastoma models. The GAS41 compound targets epigenetic dysregulation tied to NSCLC pathogenesis; the BTK work highlights more selective scaffolds versus ibrutinib aimed at cancer stem cell‑driven resistance in GBM. Both programs remain preclinical but expand mechanistic approaches under active exploration in oncology.